Taiwanese diabetes management startup raises $3M for overseas expansion

Diary feature of the Health2Sync Mobile App--Courtesy of Health2Sync

Diabetes management startup Health2Sync raised $3 million in a Series A round, which it will use toward product development and to drive growth in markets including Japan, China and Southeast Asia.

Founded in 2013, the Taiwanese company offers patients a mobile app and smart cable to connect their glucose meters to their smartphones via the audiojack or infrared. It markets a patient management platform to healthcare providers. The platform is available in Taiwan and the U.S.

The platform is built on using data to help patients understand the factors that affect blood glucose and how to effect lifestyle changes to better manage their disease, according to a statement. A patient can manually record exercise, food and medication information in the app. He or she can also manually enter glucose readings, though the smart cable enables the automatic sync of data from a glucose meter. The app then turns the data into easy-to-read graphs, such as trend lines and pie charts, which can then be shared via email.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Patients may connect to healthcare providers in the app to give them access to their glucose data and activity and help them manage their diabetes more effectively. Patients may also add “partners” in the app, or people with whom they want to share data.

“While half of the global diabetic population is in Asia, the region is underserved when it comes to daily and personalized care,” said Health2Sync CEO Ed Deng in the statement. "By leveraging technology and catering to patient needs, we have demonstrated clinical efficacy.  With the new capital, we will be able to continue our mission to provide personalized care for all diabetics.”

The Series A round was led by WI Harper Group, with participation from Cherubic Ventures, iSeed Ventures and SparkLabs Global Ventures.

- here's the statement

Related Articles:
Dexcom launches data sharing in cloud-based diabetes management
Medtronic partners with LA startup for diabetes, chronic disease management tools
Silicon Valley startup brings in $44.5M for cloud-based diabetes management tech

Read more on

Suggested Articles

The FDA warned healthcare providers about cybersecurity vulnerabilities within certain clinical information systems made by GE Healthcare.

Weeks after receiving FDA approval for its in-office eardrum tube device, Tusker Medical has been picked up by Smith & Nephew for an undisclosed sum.

As public fascination with at-home DNA tests begins to wane, 23andMe announced that it will lay off about 100 of its staff, according to CNBC.